Whose tissue is it anyway?

Article Abstract:

Intellectual property (IP) law in the US allows researchers to capitalize on their contributions to a research enterprise, but it denies donors of biological materials the right to compensation for their contributions. It is suggested that a new tax on cell and tissue products derived from a donor could provide a means of ensuring a fairer distribution of the results of regenerative medicine and the commercial use of tissue in general.

Legal issues & crime, Government regulation (cont), Government regulation, Legal/Government Regulation, Interpretation and construction, Laws, regulations and rules, Donation of organs, tissues, etc., Tissue donation

---

Developing an intellectual property portfolio for the academic or not-for-profit institution

Article Abstract:

Selectivity is the key to maximize revenue from an intellectual property (IP) licensing program. Various considerations are reviewed that can help academic and other not-for-profit research institutions to do a better job of selecting the most promising innovations to protect and find the best qualified licensees to bring the technology to market.

Research and Development in the Physical, Engineering, and Life Sciences, Research and Testing Services, Medical Research, Epilepsy & Muscle Disease R&D, Administration of Public Health Programs, Health Research Programs, Medicine, Experimental

---

The emerging role of academia in commercializing innovation

Article Abstract:

The universities migration into more translational research are likely to enhance their ability to capitalize on Intellectual Property (IP) assets and ultimately could reduce the internal cost of producing new medicines. The academic institutions provide the basic biological discoveries that form the basis for majority of the biotech enterprises.

Economic aspects, Pharmaceutical research

Similar abstracts:

• Abstracts: Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display
• Abstracts: P-cards travel different roads to the same efficiencies. Recruiting creativity
• Abstracts: Haplotyping in biomedicine--practical challenges. Programmable ligand-controlled riboregulators of eukaryotic gene expression
• Abstracts: Converting biotech scientists to managers. Giving patients a say: how to work with patient advocacy groups. Signal transduction inhibitors-a work in progress

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.